Current Affairs - Science - Discussion

Awiqli, developed by Novo Nordisk, is the world's first once-weekly basal insulin introduced in India for the treatment of adult diabetes. The medicine is designed to reduce the burden of daily insulin injections by requiring only one injection every week, reducing the annual number of injections from 365 to 52. It is administered through a pre-filled pen device and works by binding to the blood protein albumin, which creates a reservoir that releases insulin steadily over seven days. This helps maintain stable blood glucose levels and improves treatment convenience. Awiqli can be used by eligible patients with Type 2 diabetes either alone or with other medicines, while patients with Type 1 diabetes must use it together with short-acting insulin during mealtimes.